Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Phase 4
Completed
- Conditions
- HypertensionLeft Ventricular Hypertrophy
- Registration Number
- NCT00139555
- Lead Sponsor
- Novartis
- Brief Summary
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 125
Inclusion Criteria
- Males or female patients ≥ 55 years of age
- LVH as confirmed by echocardiogram
- Patients with high risk hypertension, currently treated or already taking antihypertensive medication
Read More
Exclusion Criteria
- Renal artery stenosis
- Symptomatic heart failure or known ejection fraction < 40%
- Myocardial infarction or stroke within 6 months
- Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
- Pregnant or lactating females
- Cancer within the last 5 years
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in left ventricular mass index after 52 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in aorta function assessed blood pressure measurements after 52 weeks Change from baseline in left ventricular mass after 52 weeks Change from baseline in diastolic function after 52 weeks Change from baseline in markers of fibrosis and increased heart size after 52 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States